Key facts
- This page summarizes Anders Ullman's Form 4 filing for Verona Pharma plc (VRNA).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 05 Aug 2025, 20:16.
Anders Ullman - 01 Aug 2025 Form 4 Insider Report for Verona Pharma plc (VRNA)
- Form type
- 4
- Accepted by SEC
- 05 Aug 2025, 20:16:06 UTC
- Previous filing
- 29 Apr 2025
- Next filing
- 08 Oct 2025
- SEC filing
- View on sec.gov
- Reporting owner signature
- /s/ Andrew Fisher, Attorney-in-fact for Anders Ullman
Source evidence
5 source fields
Reporting owner
1 detail
Key filing fact
Anders Ullman filed Form 4 for Verona Pharma plc (VRNA) on 05 Aug 2025.
Change
- Previous filing in this sequence was filed on 29 Apr 2025.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
See Original Filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001836816
Primary reporting owner
Ullman Anders
- Relationship
- Director
- Address
- 3 MORE LONDON RIVERSIDE, LONDON, UNITED KINGDOM
- Signature
- /s/ Andrew Fisher, Attorney-in-fact for Anders Ullman
- Signature date
- 05 Aug 2025
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
VRNA
transaction
Ordinary Shares
Options Exercise
- Transaction value
- $0
- Shares
- +24,000
- Change %
- +7.2%
- Price
- $0.000000
- Shares after
- 358,856
- Date
- 01 Aug 2025
- Ownership
- Direct
- Footnotes
- F1, F2
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
VRNA
transaction
Derivative
Restricted Stock Units
Options Exercise
- Transaction value
- $0
- Shares
- -24,000
- Change %
- -25%
- Price
- $0.000000
- Shares after
- 72,000
- Date
- 01 Aug 2025
- Ownership
- Direct
- Underlying class
- Ordinary Shares
- Underlying amount
- 24,000
- Exercise price
- Footnotes
- F1, F3, F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 4 footnotes
Footnote F1
Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer.
Footnote F2
Consists of 358,856 Ordinary Shares represented by 44,857 ADSs.
Footnote F3
Represents an award of Restricted Share Units ("RSUs") covering ADSs, which is presented in terms of the equivalent number of Ordinary Shares underlying the ADSs. Each RSU represents a contingent right to receive one (1) ADS of the Issuer. Each ADS represents eight (8) Ordinary Shares of the Issuer. The RSUs have no expiration date.
Footnote F4
The RSUs vest as to 25% of the total shares on each of August 1, 2025, November 1, 2025, February 1, 2026 and May 1, 2026 subject to the Reporting Person's continued service to the Issuer on each vesting date.
SEC remarks
Exhibit 24 - Power of Attorney.